Tecogen (NYSE American: TGEN) extends John Hatsopoulos advisory term to 2028
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Tecogen Inc. reported that it has extended its Advisory Agreement with Mr. John N. Hatsopoulos. The agreement, originally dated January 18, 2018 and previously amended in 2019 and 2023, will now run through March 31, 2028. The company’s Board of Directors approved the extension by Unanimous Written Consent on April 7, 2026, and the letter agreement documenting this extension is filed as an exhibit.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Advisory Agreement original date: January 18, 2018
Advisory Agreement amendments: July 22, 2019; July 19, 2023
Extended advisory term end date: March 31, 2028
+2 more
5 metrics
Advisory Agreement original date
January 18, 2018
Initial Advisory Agreement between Tecogen and John N. Hatsopoulos
Advisory Agreement amendments
July 22, 2019; July 19, 2023
Prior amendments to the Advisory Agreement
Extended advisory term end date
March 31, 2028
New expiration of Advisory Agreement after latest extension
Board approval date
April 7, 2026
Unanimous Written Consent approving extension
Letter agreement date
April 8, 2026
Date of letter agreement extending Advisory Agreement
Key Terms
Advisory Agreement, Unanimous Written Consent, Emerging growth company, Exhibit 99.1, +1 more
5 terms
Advisory Agreement financial
"extend the term of the Advisory Agreement dated January 18, 2018"
Unanimous Written Consent regulatory
"approved by Unanimous Written Consent of the Company’s Board of Directors"
Emerging growth company regulatory
"Emerging growth company o Item 8.01. Other Events."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Exhibit 99.1 regulatory
"Exhibit 99.1 | Letter Agreement dated April 8, 2026 extending the term"
Exhibit 99.1 is a label used in regulatory filings to identify a specific attached document, most often a company press release or investor presentation filed with securities regulators. For investors it matters because it marks an official, contemporaneous source of information directly tied to a filing—like the original news article pinned to a legal record—so traders and analysts treat it as an authoritative statement that can move a stock or clarify a company’s situation.
Other Events regulatory
"Item 8.01. Other Events. On April 8, 2026, Tecogen Inc."
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 8, 2026
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation)
| (Commission File Number) | (IRS Employer Identification No.) | |||||||
| (Address of Principal Executive Offices and Zip Code) | ||
(781 ) 466-6400
(Registrant's telephone number, including area code)
Securities registered or to be registered pursuant to Section 12(b) of the Act.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Title of each class | Trading Symbol | Name of exchange on which registered | ||||||
| Common Stock, $0.001 par value per share | TGEN | NYSE American, LLC | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01. Other Events.
On April 8, 2026, Tecogen Inc., a Delaware corporation (the “Company”) agreed to extend the term of the Advisory Agreement dated January 18, 2018, as amended on July 22, 2019 and July 19, 2023, between the Company and Mr. John N. Hatsopoulos (the “Advisory Agreement”) through March 31, 2028. The extension of the term of the Advisory Agreement was approved by Unanimous Written Consent of the Company’s Board of Directors on April 7, 2026. A copy of the letter agreement extending the Advisory Agreement is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit | Description | ||||
| 99.1 | Letter Agreement dated April 8, 2026 extending the term of the Advisory Agreement between Tecogen Inc. and John N. Hatsopoulos. | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| TECOGEN INC. | ||||||||
By: /s/ Abinand Rangesh | ||||||||
| April 8, 2026 | Abinand Rangesh, Chief Executive Officer | |||||||
FAQ
What did Tecogen Inc. (TGEN) disclose in this 8-K filing?
Tecogen Inc. disclosed that it extended its Advisory Agreement with John N. Hatsopoulos through March 31, 2028. The Board of Directors approved this extension by Unanimous Written Consent on April 7, 2026, and the related letter agreement is filed as an exhibit.
Who is the advisor in Tecogen Inc.’s extended Advisory Agreement?
The advisor is John N. Hatsopoulos, who has an Advisory Agreement with Tecogen Inc. originally dated January 18, 2018. This agreement was previously amended in 2019 and 2023 and has now been extended further through March 31, 2028 by mutual agreement.
How long is Tecogen Inc.’s Advisory Agreement with John N. Hatsopoulos now in effect?
Tecogen Inc.’s Advisory Agreement with John N. Hatsopoulos now runs through March 31, 2028. The company and Mr. Hatsopoulos agreed to this term extension on April 8, 2026, following prior amendments to the original 2018 agreement in 2019 and 2023.
How did Tecogen Inc.’s Board approve the Advisory Agreement extension?
Tecogen Inc.’s Board of Directors approved the extension of the Advisory Agreement with John N. Hatsopoulos by Unanimous Written Consent on April 7, 2026. This means every director agreed in writing, rather than acting at a formal in-person or telephonic board meeting.
What exhibit is attached to Tecogen Inc.’s 8-K about the advisory extension?
The filing attaches Exhibit 99.1, described as a Letter Agreement dated April 8, 2026. This letter agreement documents the extension of the term of the Advisory Agreement between Tecogen Inc. and John N. Hatsopoulos and forms the key supporting document to the disclosure.
Where is Tecogen Inc. (TGEN) headquartered according to this filing?
Tecogen Inc. is headquartered at 76 Treble Cove Road, Building 1, North Billerica, Massachusetts 01862. The filing also lists the company’s main telephone number as (781) 466-6400 and notes that its common stock trades on the NYSE American under the symbol TGEN.